ERIS Lifesciences Ltd
Pharmaceuticals & Biotechnology | Small Cap
ERIS Lifesciences shows a mixed financial performance. The company excels in solvency and profitability, indicating financial stability and efficient use of resources. Growth and financial ratios are also strong, driven by significant revenue and operating profit increases. However, liquidity and efficiency ratios are areas of concern. While the company is managing its debts well and achieving high profits, it needs to improve its ability to meet short-term obligations and optimize asset turnover. Overall, ERIS Lifesciences demonstrates solid financial health with potential for improvement in specific operational areas. The healthcare industry's dynamics, including regulatory changes and market competition, could influence future performance.
Latest Report
View AllLatest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
- Valuation MetricsNeutral
- Market Metrics
- Stock Reports
- Stock News
- Growth Ratio6.00
- Financial Ratio8.00
- Profitability Ratio10.00
- Efficiency Ratio5.00
- Coverage Ratio8.40
- Solvency Ratio10.00
- Liquidity Ratio5.08
- Peer Assessment
- Management AssessmentBalanced
- Risk AssessmentBalanced
- 1 HourBullish
- 2 HoursBullish
- 4 HoursBullish
- 1 DayBullish
- 1 WeekNeutral
- 1 MonthNeutral
ERIS Lifesciences shows a mixed financial performance. The company excels in solvency and profitability, indicating financial stability and efficient use of resources. Growth and financial ratios are also strong, driven by significant revenue and operating profit increases. However, liquidity and efficiency ratios are areas of concern. While the company is managing its debts well and achieving high profits, it needs to improve its ability to meet short-term obligations and optimize asset turnover. Overall, ERIS Lifesciences demonstrates solid financial health with potential for improvement in specific operational areas. The healthcare industry's dynamics, including regulatory changes and market competition, could influence future performance.
Latest Report
View AllLatest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
Overall Valuation Score
P/E RATIO (TTM)
82.25
Industry Median
28.62
Small Cap Median
27.17
P/E RATIO
32.39
P/B RATIO
5.14
Industry Median
3.17
Small Cap Median
2.62
P/S RATIO
6.24
Industry Median
3.42
Small Cap Median
2.55
Others
PEG RATIO
0.00
EV/EBITDA RATIO
18.39
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹1448.4 as on Jun 21, 2026.
Unlock Live Chart
Please login to view interactive real-time technical charts powered by TradingView.
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
0.00
Today's Low
0.00
Today's High
Concall Report⬤20th Feb 26
Q3 FY26 Earnings Conference Call
BULLISH SENTIMENT
The company demonstrates strong growth in revenue, operating profit, and assets, but earnings and net income growth are negative. This indicates operational improvements and asset expansion, but profitability is declining. The company needs to address the factors impacting earnings and net income to ensure sustainable growth across all key metrics.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 11.14 | 25.09 | 19.23 | 44.05 | 8.12 |
| Operating Profit Growth Rate | 13.46 | 10.22 | 25.6 | 50.37 | 10.02 |
| Earnings Per Share (EPS) Growth | 14.22 | -5.96 | 2.56 | -10.34 | 73.07 |
| Asset Growth Rate | 24.71 | 53.19 | 97.48 | 0.15 | 9.22 |
| Net Income Growth Rate | 14.37 | -7.88 | 6.15 | -5.54 | 72.8 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
The company exhibits strong financial performance in earnings per share and book value, but capital expenditures are a concern. High earnings per share and book value reflect enhanced profitability and shareholder value. The company is generating substantial profits for each share and maintaining a strong equity base. However, the company needs to manage its investments more efficiently.
| Financial Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Adjusted Earnings Per Share (Adjusted EPS) | 29.14 | 25.86 | 28.5 | 28.29 | 49.21 |
| Cash Earnings Per Share (Cash EPS) | 33.64 | 35.07 | 41.43 | 49.29 | 66.29 |
| Book Value Per Share | 136.36 | 156.86 | 184.79 | 203.93 | 278.79 |
| Dividend Per Share (DPS) | 5.98 | 7.31 | 0 | 7.24 | 7.16 |
| Capital Expenditures (CapEx) | 120 | 841 | 129 | 155 | 297 |
Adjusted Earnings Per Share (Adjusted EPS)
Cash Earnings Per Share (Cash EPS)
Book Value Per Share
Dividend Per Share (DPS)
Capital Expenditures (CapEx)
The company demonstrates excellent profitability across all key metrics. High margins, returns on capital, equity, and assets indicate efficient and effective management. The company is generating substantial profits from its operations and investments. The company is maximizing shareholder wealth and maintaining a strong competitive position.
| Profitability Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Profit Margin | 31.48 | 25.04 | 24.59 | 24.29 | 26.85 |
| Return on Capital Employed (ROCE) | 25 | 17 | 11 | 12 | 14 |
| Return on Equity (ROE) | 21.27 | 17.03 | 15.35 | 13.13 | 16.6 |
| Return on Assets (ROA) | 21.97 | 15.81 | 10.05 | 15.09 | 15.2 |
| Operating Margin | 36.3 | 31.99 | 33.7 | 35.18 | 35.79 |
| Net Margin | 30.14 | 22.2 | 19.76 | 12.96 | 20.71 |
Gross Profit Margin
Return on Capital Employed (ROCE)
Return on Equity (ROE)
Return on Assets (ROA)
Operating Margin
Net Margin
The company demonstrates mixed efficiency in utilizing its assets. Inventory management and sales are reasonably well-managed, but fixed asset and capital turnover are low. This suggests potential underutilization of fixed assets and capital. Improving the turnover of fixed assets and overall capital could significantly enhance the company's operational efficiency and profitability.
| Efficiency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Fixed Asset Turnover Ratio | 1.47 | 0.66 | 0.47 | 0.55 | 0.6 |
| Inventory Turnover Ratio | 8.71 | 10.14 | 9.47 | 8.36 | 5.93 |
| Receivables Turnover Ratio | 8.95 | 7.42 | 5.62 | 6.57 | 5.49 |
| Days Sales in Inventory Ratio | 41.91 | 36 | 38.54 | 43.66 | 61.55 |
| Receivable Days | 40.78 | 49.19 | 64.95 | 55.56 | 66.48 |
| Capital Turnover Ratio | 0.68 | 0.58 | 0.61 | 0.62 | 0.64 |
Fixed Asset Turnover Ratio
Inventory Turnover Ratio
Receivables Turnover Ratio
Days Sales in Inventory Ratio
Receivable Days
Capital Turnover Ratio
The company's ability to cover its interest expenses is very strong. However, its equity dividend coverage is just average. The company is easily meeting its debt obligations, but its dividend payouts are not as well-covered. The company is able to maintain its debt obligations comfortably.
| Coverage Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Interest Coverage Ratio | 111.5 | 16.58 | 6.07 | 3.12 | 4.31 |
| Equity Dividend Coverage Ratio | 5 | 3.85 | 3.57 | 6.25 |
Interest Coverage Ratio
Equity Dividend Coverage Ratio
The company's long-term financial stability is excellent. Low debt levels relative to equity and assets demonstrate a conservative approach to financing, reducing the risk of financial distress. A strong equity base provides a solid foundation for future growth and resilience against economic downturns. The company is well-positioned to manage its long-term obligations and capitalize on growth opportunities without excessive reliance on debt.
| Solvency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Debt Ratio | 0.04 | 0.24 | 0.21 | 0.39 | 0.2 |
| Debt to Equity Ratio | 0.04 | 0.32 | 0.27 | 0.64 | 0.25 |
| Equity Ratio | 0.96 | 0.76 | 0.79 | 0.61 | 0.8 |
| Debt To Asset Ratio | 0.04 | 0.2 | 0.1 | 0.27 | 0.14 |
Debt Ratio
Debt to Equity Ratio
Equity Ratio
Debt To Asset Ratio
The company's ability to meet its short-term obligations is a mix of strengths and weaknesses. While the quick ratio and operating cash flow ratio are at acceptable levels, the current and cash ratios suggest potential difficulties in covering immediate liabilities. This indicates that while the company can convert some assets into cash, its overall liquidity position needs to be stronger to ensure smooth operations and financial flexibility.
| Liquidity Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Current Ratio | 3.27 | 1.5 | 0.69 | 0.62 | 0.79 |
| Quick Ratio | 2.76 | 1.25 | 0.64 | 0.46 | 0.61 |
| Cash Ratio | 0.22 | 0.11 | 0.41 | 0.11 | 0.03 |
| Operating Cash Flow Ratio | 1.62 | 0.56 | 0.14 | 0.51 | 0.22 |
Current Ratio
Quick Ratio
Cash Ratio
Operating Cash Flow Ratio
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | J B Chemicals & Pharmaceuticals Ltd | 8.14 | 49.64 | Overvalued | 1107.00 | 41.98 | 709.00 |
| 2 | Gland Pharma Ltd | 7.91 | 35.27 | Overvalued | 1630.00 | 78.88 | 1027.00 |
| 3 | Neuland Laboratories Ltd | 7.84 | 61.14 | Highly Overvalued | 574.00 | 283.01 | 364.00 |
| 4 | Granules India Ltd | 7.73 | 32.77 | Highly Overvalued | 1185.00 | 16.17 | 595.00 |
| 5 | Ajanta Pharma Ltd | 7.72 | 36.27 | Neutral | 1395.00 | 75.78 | 1056.00 |
| 6 | Alembic Pharmaceuticals Ltd | 7.54 | 22.23 | Undervalued | 1118.00 | 32.58 | 671.00 |
| 7 | Syngene International Ltd | 7.44 | 56.08 | Overvalued | 918.00 | 7.55 | 317.00 |
| 8 | Emcure Pharmaceuticals Ltd | 7.40 | 36.42 | Neutral | 1865.00 | 38.66 | 941.00 |
| 9 | ERIS Lifesciences Ltd | 7.15 | 32.39 | Neutral | 1120.00 | 17.61 | 648.00 |
| 10 | Piramal Pharma Ltd | 5.83 | -64.86 | Neutral | 922.00 | 5.27 | -326.00 |
| 11 | Jubilant Pharmova Ltd | 5.71 | 38.62 | Neutral | 1260.00 | 1.25 | 398.00 |
| 12 | Natco Pharma Ltd | 5.69 | 11.22 | Neutral | 1436.00 | 71.55 | 1418.00 |
| 13 | Jeena Sikho Lifecare Ltd | 5.52 | 31.22 | Neutral | 349.00 | 17.87 | 222.00 |
| 14 | Wockhardt Ltd | 5.07 | 153.40 | Neutral | 652.00 | 19.51 | 199.00 |
| 15 | Pfizer Ltd | 3.45 | 45.16 | Neutral | -82.00 | 157.92 | 300.00 |
| 16 | Procter & Gamble Health Ltd | 3.45 | 31.71 | Neutral | 457.00 | 196.94 | 327.00 |
| 17 | Sanofi India Ltd | 3.45 | 18.59 | Neutral | 491.00 | 134.52 | 413.00 |
The management of ERIS Lifesciences demonstrates a mixed performance. The company shows strong revenue growth and maintains operational efficiency. However, declining profit growth and increased borrowings raise concerns. Overall, the management's effectiveness is rated as mixed, reflecting strengths in revenue generation and areas for improvement in financial prudence. Recent profit growth concerns and increased debt levels temper an otherwise positive outlook.
| Category | Metric | Value | Assessment |
|---|---|---|---|
| PROS | Sales Growth | [TTM: 44%] | strong revenue expansion |
| Operating Profit Margin | [36%] | operational efficiency is maintained | |
| CONS | Compounded Profit Growth (3Y, TTM) | [-5%, -10%] | profit growth is declining |
| Debt/Equity Ratio | [2,478 Cr.] | leverage is increasing |
Financial Performance & Growth
ERIS Lifesciences demonstrates strong Sales Growth coupled with declining Profit Growth.
Sales Growth: The company has shown robust sales growth over the years. Compounded Sales Growth is reported as 29% over the last 3 years and a TTM of 44% indicating strong revenue expansion. Profit Growth: The company's compounded profit growth shows a concerning trend. The 3-year compounded profit growth is -5% and the TTM is -10%, indicating challenges in maintaining profitability.
| Metric | 2017-2019 | 2020-2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Sales Growth (%) | 17.83% | 11.78% | 25.10% | 19.23% | 44.02% |
| Profit Growth (%) | 22.81% | 18.84% | -7.91% | 6.15% | -5.52% |
Capital Efficiency & Returns
The capital efficiency and returns for ERIS Lifesciences show a mixed performance. While Return on Equity (ROE) and Return on Capital Employed (ROCE) have historically been strong, there's a recent decline that warrants attention.
Return on Capital Employed (ROCE): The ROCE figures indicate a decrease over the years.
Return on Equity (ROE): Similar to ROCE, ROE has also declined.
| Metric | 2014-2016 | 2017-2019 | 2020-2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| ROCE (%) | 54.67% | 33.67% | 25.67% | 17% | 11% | 12% |
| ROE (%) | NA | NA | NA | 16% | 11% | 13% |
Financial Health & Prudence
The financial health and prudence of ERIS Lifesciences reveal some concerning trends, particularly in debt management. The company has seen a significant increase in borrowings, which impacts its overall financial stability.
Debt Management: The borrowings have substantially increased over the past few years.
| Metric | 2017-2019 | 2020-2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Borrowings (Cr) | 184.67 | 31.67 | 877 | 2,781 | 2,478 |
Shareholding & Ownership Structure
The shareholding and ownership structure of ERIS Lifesciences indicate a stable promoter holding with increasing DII participation, though FII investment has decreased recently.
Promoter Holding: Promoter holding has remained relatively stable, indicating continued confidence.
Institutional Holding (FII/DII): DII holding has increased, suggesting growing confidence from domestic institutions.
| Metric | Jun 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Promoter Holding (%) | 52.30 | 52.86 | 54.90 | 54.85 |
| FII Holding (%) | 15.35 | 14.86 | 14.27 | 8.43 |
| DII Holding (%) | 10.66 | 10.02 | 15.63 | 18.07 |
The risk assessment for ERIS Lifesciences indicates a moderate level of risk. The company exhibits strengths in sales growth but faces challenges related to declining profit growth and increased debt. Overall, the risk is assessed as moderate, requiring careful monitoring of key financial metrics.
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 101440.06Bullish
- SMA 201428.99Bullish
- SMA 501400.39Bullish
- EMA 101439.02Bullish
- EMA 201428.37Bullish
- EMA 501407.86Bullish
- DEMA 101448.41Bearish
- DEMA 201447.23Bearish
- DEMA 501430.10Bullish
- TEMA 101446.92Bearish
- TEMA 201451.50Bearish
- TEMA 501442.73Bullish
- MACD14.03Bullish
- ADX42.20Strong Trend
- IndicatorValueSignal
- RSI61.00Neutral
- CCI46.30Neutral
- ROC 90.90Bullish
- ROC 142.43Bullish
- ROC 255.37Bullish
- Stoch K64.03Neutral
- Stoch D59.18Neutral
- IndicatorValueSignal
- BB Upper1461.16Neutral
- BB Middle1428.99Neutral
- BB Lower1396.83Neutral
- ATR17.80High Volatility
- IndicatorValueSignal
- MFI54.46Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 2 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 101433.14Bullish
- SMA 201409.41Bullish
- SMA 501388.21Bullish
- EMA 101432.33Bullish
- EMA 201417.09Bullish
- EMA 501396.70Bullish
- DEMA 101449.53Bearish
- DEMA 201439.53Bullish
- DEMA 501415.93Bullish
- TEMA 101452.55Bearish
- TEMA 201449.75Bearish
- TEMA 501428.82Bullish
- MACD17.76Bullish
- ADX44.30Strong Trend
- IndicatorValueSignal
- RSI67.78Neutral
- CCI84.24Neutral
- ROC 92.42Bullish
- ROC 145.07Bullish
- ROC 255.71Bullish
- Stoch K78.68Neutral
- Stoch D78.01Neutral
- IndicatorValueSignal
- BB Upper1463.00Neutral
- BB Middle1409.41Neutral
- BB Lower1355.82Neutral
- ATR20.76High Volatility
- IndicatorValueSignal
- MFI65.33Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 4 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 101408.67Bullish
- SMA 201392.13Bullish
- SMA 501379.29Bullish
- EMA 101416.06Bullish
- EMA 201400.87Bullish
- EMA 501383.71Bullish
- DEMA 101436.28Bullish
- DEMA 201420.34Bullish
- DEMA 501401.41Bullish
- TEMA 101444.80Bullish
- TEMA 201432.24Bullish
- TEMA 50N/AN/A
- MACD16.24Bullish
- ADX18.47Weak Trend
- IndicatorValueSignal
- RSI66.71Neutral
- CCI143.06Overbought
- ROC 94.02Bullish
- ROC 145.86Bullish
- ROC 253.03Bullish
- Stoch K83.07Overbought
- Stoch D87.04Overbought
- IndicatorValueSignal
- BB Upper1444.52Overbought
- BB Middle1392.12Neutral
- BB Lower1339.73Neutral
- ATR28.71High Volatility
- IndicatorValueSignal
- MFI60.15Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 33 Technical Indicators From The 1 Day Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 101392.69Bullish
- SMA 201380.28Bullish
- SMA 501377.66Bullish
- SMA 1001368.97Bullish
- SMA 2001483.38Bearish
- EMA 101402.26Bullish
- EMA 201388.88Bullish
- EMA 501378.89Bullish
- EMA 1001398.28Bullish
- EMA 2001436.17Bullish
- DEMA 101421.91Bullish
- DEMA 201404.94Bullish
- DEMA 501376.25Bullish
- DEMA 1001344.45Bullish
- DEMA 2001407.31Bullish
- TEMA 101433.56Bullish
- TEMA 201415.42Bullish
- TEMA 501401.83Bullish
- TEMA 1001347.39Bullish
- TEMA 2001315.13Bullish
- MACD13.74Bullish
- ADX16.50Weak Trend
- IndicatorValueSignal
- RSI61.76Neutral
- CCI232.80Overbought
- ROC 145.08Bullish
- ROC 255.42Bullish
- Stoch K90.44Overbought
- Stoch D80.37Overbought
- IndicatorValueSignal
- BB Upper1433.28Overbought
- BB Middle1380.27Neutral
- BB Lower1327.27Neutral
- ATR44.78High Volatility
- IndicatorValueSignal
- MFI53.65Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 21 Technical Indicators From The 1 Week Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 201367.70Bullish
- SMA 501524.33Bearish
- EMA 201395.08Bullish
- EMA 501437.54Bearish
- DEMA 201346.12Bullish
- DEMA 501441.62Bearish
- TEMA 201352.26Bullish
- TEMA 501340.62Bullish
- MACD-31.69Bullish
- ADX11.31Weak Trend
- IndicatorValueSignal
- RSI48.18Neutral
- CCI-68.76Neutral
- ROC 143.23Bullish
- ROC 25-10.63Bearish
- Stoch K57.45Neutral
- Stoch D53.57Neutral
- IndicatorValueSignal
- BB Upper1444.72Neutral
- BB Middle1367.70Neutral
- BB Lower1290.68Neutral
- ATR104.39Low Volatility
- IndicatorValueSignal
- MFI60.75Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 25 Technical Indicators From The 1 Month Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 61376.42Bullish
- SMA 121526.20Bearish
- SMA 241423.78Bearish
- EMA 61396.26Bullish
- EMA 121426.54Bearish
- EMA 241358.39Bullish
- DEMA 61342.47Bullish
- DEMA 121432.89Bearish
- DEMA 241543.13Bearish
- TEMA 61328.02Bullish
- TEMA 121340.96Bullish
- TEMA 241515.14Bearish
- MACD213.80Bearish
- ADX38.29Strong Trend
- IndicatorValueSignal
- RSI57.58Neutral
- CCI67.38Neutral
- ROC 2556.15Bullish
- ROC 50103.14Bullish
- Stoch K64.94Neutral
- Stoch D76.85Neutral
- IndicatorValueSignal
- BB Upper1803.79Neutral
- BB Middle1464.68Neutral
- BB Lower1125.56Neutral
- ATR222.99Low Volatility
- IndicatorValueSignal
- MFI54.98Neutral